메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

라이프

Global Fitness Leader Anytime Fitness Accelerates Asia Expansion with New Regional Agents for Taiwan

TAIPEI, Dec. 2, 2025 -- Anytime Fitness, the world's largest and fastest-growing fitness franchise, continues its momentum across Asia with significant new developments. With more than 5,600 clubs across 40 countries and on all seven continents, the brand remains unmatched in global presence and accessibility. In Asia, growth is driven by Inspire Brands Asia (IBA), the exclusive regional master franchisee for Singapore, Malaysia, Thailand, Taiwan region, the Philippines, Vietnam, Hong Kong SAR, and Indonesia. With a rapidly expanding network of over 520 clubs, the region is now
- 노기식 기자
- 2025-12-02 21:09
Health In Tech Announces Voluntary Extension of Lock-Up Period

STUART, Fla., Dec. 2, 2025 -- Health In Tech (Nasdaq: HIT), an Insurtech platform company backed by third-party AI technology, today announced that its executive management team, vice presidents across functions, and Board of Directors have voluntarily agreed to extend the lock-up restrictions on all shares they hold for an additional six months beyond the original twelve-month lock-up established at the time of the Company's final prospectus issued in connection with its initial public offering on December 20, 2024. Under this voluntary extension, all shares hel
- 김갑성 기자
- 2025-12-02 21:00
HoneyNaps' AI Sleep-Diagnosis Software SOMNUM™ Selected as a 2025 Next Generation World Class Product at MOTIR Certification Ceremony

[ 메디채널 김갑성 기자 ] Recognized at the official 2025 World Class Product of Korea Certification Ceremony held at Lotte Hotel World, Seoul Certification affirms SOMNUM's potential to lead the global market within seven years HoneyNaps accelerates global expansion: "We aim to become Korea's leading SleepTech innovator" BOSTON, Dec. 2, 2025 -- HoneyNaps, an AI-based sleep-medicine company, announced that its AI PSG Auto-scoring software SOMNUM™ has been designated as a 2025 Next Generation World Class Product by Korea's Ministry of Trade, Industry, and Resources (MOTIR) and
- 김갑성 기자
- 2025-12-02 19:00
Neusoft Medical Systems Unveils World's First 8cm Wide-Coverage Photon-Counting CT and Other Premium Innovations at RSNA 2025

CHICAGO, Dec. 2, 2025 -- Neusoft Medical Systems Co., Ltd. ("Neusoft Medical"), a global leader in medical imaging, is showcasing its comprehensive portfolio of intelligent healthcare innovations at the Radiological Society of North America (RSNA) 2025 annual meeting. The highlight of the exhibition is the groundbreaking launch of the NeuViz P10, the world's first 8cm wide-coverage photon-counting CT. It is joined by several other high-end imaging systems and AI-integrated clinical solutions. The live demonstration presents a full-cycle intelligent imaging ecosystem s
- 김갑성 기자
- 2025-12-02 17:26
Antengene Announces IND Approval in China for Phase Ib/II Study of ATG-022 (CLDN18.2 ADC) in Combination with KEYTRUDA® (Pembrolizumab) ± Chemotherapy

SHANGHAI and HONG KONG, Dec. 2, 2025 -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune disease, solid tumors and hematological malignancies indications, today announced that the China National Medical Products Administration (NMPA) has approved the investigational new drug (IND) application for the Phase Ib/II CLINCH-2 study evaluating ATG-022 (CLDN18.2 antibody-drug conjugate [ADC]) i
- 김갑성 기자
- 2025-12-02 17:00
ZAGENO Receives Frost & Sullivan's 2025 Global Company of the Year Recognition for Excellence in Life Sciences E-commerce Leadership

[ 메디채널 김갑성 기자 ] ZAGENO earns global recognition for driving innovation, operational efficiency, and transformative customer value across the life sciences e-commerce ecosystem. SAN ANTONIO, Dec. 2, 2025 -- Frost & Sullivan is pleased to announce that ZAGENO has been recognized with the 2025 Global Company of the Year Recognition in the life sciences e-commerce industry for its outstanding achievements in digital innovation, customer value enhancement, and strategic market execution. This recognition highlights ZAGENO's consistent leadership in driving measurable outcomes, strengt
- 김갑성 기자
- 2025-12-02 15:00
Accord Healthcare Announces Launch of Denosumab∇ - Second Biosimilar in Bone Health

∇ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. LONDON, Dec. 2, 2025 -- Accord Healthcare today announced the launch of Osvyrti (denosumab), a biosimilar to Prolia® (Amgen), and Jubereq (denosumab), a biosimilar to Xgeva® (Amgen), following the scheduled expiry of the reference medicine's patent on 27 November 2025. Both medicines were approved by the European Medicines Agency (EMA) in September of this year following trials versus their reference product showing they are highly similar to the P
- 김갑성 기자
- 2025-12-02 15:00
Amaran Biotech's Vaccine Adjuvant AB-801 Receives FDA Drug Master File (DMF) Filing Acknowledgement

HSINCHU, Dec. 2, 2025 -- Amaran Biotech, a next-generation Contract Development and Manufacturing Organization (CDMO), announced that its self-developed, GMP-grade high-purity vaccine adjuvant AB-801 has received an Acknowledgement Letter from the U.S. Food and Drug Administration (FDA) for its Type II Drug Master File (DMF). Amaran Biotech is now the first adjuvant supplier in Taiwan to obtain FDA DMF Acknowledgement. This milestone underscores the company's strong capabilities in adjuvant process development, quality management, and international regulatory compliance, while further enablin
- 김갑성 기자
- 2025-12-02 14:42
GC Biopharma's Varicella Vaccine Strain 'MAV/06' Listed in WHO Position Paper

Officially recognized by WHO as a standard varicella vaccine strain alongside Oka Interchangeability endorsed, enhancing global supply security YONGIN, South Korea, Dec. 2, 2025 -- GC Biopharma (006280.KS), a global biopharmaceutical company, today announced that its proprietary varicella vaccine strain MAV/06 has been included in the World Health Organization (WHO) Position Paper on varicella vaccination, published on November 21. WHO Position Paper serves as the most authoritative global guidance for immunization policy, developed by the Strategic
- 김갑성 기자
- 2025-12-02 13:00
쭐랄롱꼰대 개발 AI '딥 GI', 위장관암 진단 혁신 기대

[ 메디채널 김갑성 기자 ] 방콕 2025년 12월 2일 -- 쭐랄롱꼰대학교 의과대학이 공과대학과 협력해 '딥 GI(Deep GI)'라는 혁신적인 인공지능(AI) 기술을 개발했다. 이 기술은 일반의가 전문의와 동등한 수준으로 위장관암(胃腸管癌)을 발견하는 데 도움을 줄 수 있게 설계됐다. 수십만 건의 내시경 영상으로 훈련된 이 시스템은 태국 식품의약품국(Thai FDA) 승인을 획득해 현재 전국 배포 및 상업화 준비를 진행 중이다. 대장암은 태국인들 사이에서 세 번째로 흔한 암으로, 특히 50세 이상이 고위험군에 속한다. 그러나 태국에는 내시경 전문의가 약 1000명에 불과해 검진 수요를 충족할 만큼 잘 훈련된 전문 인력이 부족하다. 딥 GI는 내시경 검사 시 폴립(용종)과 같은 비정상 병변을 실시간으로 표시해주는 '조력자(co-pilot)' 역할을 수행하며 이러한 격차를 해소하는 데 도움을 준다. 이를 통해 의사는 보다 자신감 있고 효율적으로 최종 진단을 내릴 수 있게 된다. 2022년 완료된 딥 GI 1단계는 대장암 검출에 집중했다. 1단계의 성공은 2025년 6월 딥 GI 2단계 출시로 이어졌다. 2단계에서는
- 김갑성 기자
- 2025-12-02 10:45

이전

71 72 73 74 75 76 77 78 79 80

많이 본 기사

최근기사

2026-03-03_TUE

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2026년 03월 03일 10시 40분